Analyze LHON Treatment Costs and Access

Background

LHON treatments range from relatively affordable oral neuroprotectants (Idebenone) to cutting-edge gene therapies that can cost hundreds of thousands of dollars. Access varies dramatically by country, insurance status, and the specific mutation a patient carries. For patients and families, understanding the cost landscape is critical for treatment planning.

What Needs to Be Done

Create a comprehensive treatment cost and access analysis:

1. Idebenone (Raxone/Catena) — Pricing in EU, UK, Japan, and other approved markets. Off-label cost in the US
2. Lenadogene Nolparvovec (Lumevoq) — Gene therapy pricing where approved, reimbursement negotiations
3. NR082 (Neurophth) — Current trial access, anticipated pricing if approved
4. Emerging therapies — TALED gene editing, stem cell approaches — estimated cost projections
5. Access barriers — Insurance denial rates, prior authorization requirements, geographic restrictions
6. Patient support — Compassionate use programs, patient assistance foundations, clinical trial access

Why This Matters

Cost is often the biggest barrier between a patient and treatment. By mapping the full cost and access landscape, we can help patients find affordable options and help advocacy organizations target policy changes where they’re needed most.

How to Submit

Submit your results by opening a GitHub issue with the label treatment-cost-analysis. Include your structured comparison tables and access assessment.